Tübingen-based vaccine manufacturer: Curevac starts at a blistering pace in the stock market

The tübingen-based biotech company Curevac has celebrated a fast and furious debut on the American technology stock exchange Nasdaq. The shares traded in early

Tübingen-based vaccine manufacturer: Curevac starts at a blistering pace in the stock market

The tübingen-based biotech company Curevac has celebrated a fast and furious debut on the American technology stock exchange Nasdaq. The shares traded in early trading on Friday just under $ 49, with more than three times their issue price, –they were 16 dollars at the upper end of the price range spent. Progress in the development of the Corona vaccine had boosted the interest of the investors. Also the Interview with the F. A. S. shows the Curevac CEO Franz-Werner Haas is optimistic.Already at an issue price Curevac has a rating with the equivalent of up to 2.4 billion euros –800 million more a few weeks ago, as, among other things, the German StaatsbankKfWeingestiegen was. Now the market capitalization is already more than seven billion euros.

With the IPO, Curevac received fresh money will primarily flow in the Corona vaccine. First of all, 13,33 million shares were issued to each 16 dollars, so that the organization 213 million dollars in flow, such as Curevac announced. The new investors can purchase in the weeks after the initial note, an additional two million shares. Thus, the revenue would increase for CureVac to $ 245 million. The majority shareholder is Dietmar Hopp, founder of software group SAP has agreed to buy the shares for a further 100 million euros at issue price.

Curevac wants to Fund with the money, especially the development of the Corona vaccine candidates until the completion of the pivotal clinical Phase 3 study and the extension of its production capacities. The proceeds are estimated to be approximately $ 150 million (130 million Euro). With a further 50 million dollars, will be expanded according to the stock exchange prospectus, the short-term production capacity. The main investor of Curevac, SAP co-founder Dietmar Hopp, will keep his company Dievini after the IPO, the control, and nearly 50 percent of the shares.The state-owned promotional Bank, KfW is still to just under 17 percent, and the pharmaceutical company GlaxoSmithKline on a good 8 per cent.

CUREVAC N. V. O. N. -- -- (--) NASDAQ 1T 1W 3M 1J 3J 5J For detail view

Curevac is in the search for a vaccine against Sars-CoV-2 one of several hopefuls to the world and not the only one who takes fresh money in the stock market. On Thursday the Hong Kong-listed shares of the Chinese company Cansino also started in Shanghai, and the rates doubled at times.

NASDAQ COMP. -- -- (--) NASDAQ INDICES 1T 1W 3M 1J had collected 3J 5J For detail view

In a recently completed round of financing Curevac, about 560 million euros from investors. Including the Federal government, announced in June the start of the KfW for a 300 million euros. The aim was therefore to prevent in the race for a Corona vaccine is a possible Takeover from abroad. According to information from the Federal government, the Initiative from the companies. As more investors around the state came Fund of the state of Qatar and GlaxoSmithKline in appearance. The British company is one of the leading vaccine companies in Europe.

at the beginning of March had invited the American President Donald Trump, the then Curevac chief Dan Menichella and other pharmaceutical representatives to the White house to learn about the vaccine search. Shortly thereafter, there was a vortex to the baden-württemberg company: according to media reports, Trump was trying to secure the vaccine exclusively for his country and offered a high amount which caused outrage. Hopp rejected, therefore, both a sale as well as an exclusive production for Trump vehemently. After that, the Federal government stepped in.

Updated Date: 14 August 2020, 14:20

You need to login to comment.

Please register or login.

RELATED NEWS